Abstract. Tectonic family member 1 (TCTN1) is one of the tectonic family members, and a regulator of the hedgehog signaling pathway, which has been studied in various cancer types, including prostate and pancreatic cancer. However, its function in thyroid cancer has not been well documented. Therefore, the present study investigated the function of TCTN1 in thyroid cancer using a loss-of-function assay. Lentivirus-mediated RNA interference was applied to downre gulate TCTN1 in the thyroid cancer cell lines, CAL62 and 8305C. A series of functional properties, including cell viability, colony formation, cell cycle and apoptosis were determined using MTT, colony formation assay and flow cytometry analyses, respectively. The results demonstrated that lentivirus-medicated RNAi could specifically suppress the expression of TCTN1 at the mRNA and protein levels in CAL62, and 8305C cells. Knockdown of TCTN1 inhibited cell growth and proliferation via inducing S phase arrest, and apoptosis. Mechanistically, the S phase arrest was accompanied by the upregulation of cyclin dependent kinase 2, cyclin A2 and downregulation of cyclin B1. Knockdown of TCTN1 induced apoptosis through increasing the expression of Bcl2-associated agonist of cell death, cleaved caspase-3 and poly(ADP-ribose)polymerase, and decreasing apoptosis regulator Bcl-2 expression. The current study highlights the essential role of TCTN1 in promoting thyroid cancer cell proliferation, and its knockdown may serve as a potential therapeutic treatment for thyroid cancer.
Introduction
Thyroid cancer, which arises from follicular cells and parafollicular cells, is one of the most rapidly growing endocrine malignancies in many countries (1) . According to the specific histological features, thyroid cancer can be classified into four types, including papillary carcinoma follicular carcinoma, medullary carcinoma and undifferentiated carcinoma (2) . Over the past few decades, diagnostic and therapeutic approaches have greatly improved long-term survival of thyroid cancer, but higher recurrence still is found in most cases (3) . Currently, molecular biology has provided possibility to investigate the pathogenesis of thyroid cancer and develop a novel effective therapeutic strategy for thyroid cancer.
Tectonic family member 1(TCTN1) is one of the tectonic family members, which is related with the development of the cilia of the eukaryotes (4) . TCTN1 can regulate the hedgehog signal pathway in mouse (5) and its mutation has influence on the Joubert Syndrome (6) (7) (8) . Recently, TCTN1 has been demonstrated to be significantly upregulated in various tumors, including glioma (9) , gastric cancer (10), prostate cancer (11) and pancreatic cancer (12) . These studies further showed that knockdown of TCTN1 could efficiently inhibit cell proliferation in vitro, suggesting it might also be an oncogene in thyroid cancer progression. However, to the best of our knowledge, the potential implication of TCTN1 in the initiation and development has not been well documented.
Therefore, in the present study, we investigate the potential role and molecular mechanism of TCTN1 in thyroid cancer in vitro. We found that the downregulation of TCTN1 suppressed thyroid cancer cell proliferation by inducing cell cycle arrest and apoptosis. These findings might provide some evidences that TCTN1 plays a crucial role in the context of tumorigenesis and proliferation of thyroid cancer.
Materials and methods
Analysis of oncomine data. In order to determine the expression of TCTN 1 in thyroid cancer, we performed data mining using Oncomine database (www.oncomine.org). An outlier analysis of TCTN 1 was performed in the thyroid cancer tissues. Lentivirus production and cell transfection. The short hairpin oligonucleotides (shTCTN1: 5'-GCT CA GAT GCA TCA GTT  CCT TCT CGA GAA GGA ACT GAT GCA TCT GAG CTT TTT  T-3' and shCon: 5'-CAA CAA GAT GAA GAG CAC CAA CTC  GAG TTG GTGC TCT TCA TCT TGT TG-3') were synthesized and cloned into the lentivirus-based vector pGP-L (System Biosciences, Inc., Palo Alto, CA, USA). Lenti virus production was followedas standard protocol by transfecting 293T cells with recombinational shRNA vector, together with pVSVG-I and pCMVΔR8.92 (Sigma, St. Louis, MO, USA). For cell transfection, thyroid cancer cells were cultured in 6-well plates and transfected with the shTCTN1 or shCon with a multiplicity of infection (MOI) of 60. After 48 h, the transfection efficiency was observed through a fluorescence microscope, and TCTN1 expression was determined using qRT-PCR and western blot assay.
Cell
qRT-PCR analysis. Trizol reagent (Invitrogen, Carlsbad, CA, USA) was used to extract RNA and reverse transcription was conducted with the revertra ace qPCR RT kit (TOYOBO Co., Ltd., Osaka, Japan Cell viability assay. After lentivirus infection, CAL62 and 8305C cells were reseeded in a 96-well plate, respectively, at a density of 2,500 cell/well. MTT assay was used to determine cell viability at five different time points (day 1, 2, 3, 4 and 5). Briefly, each well was added 20 µl of MTT (Sigma) solution and incubated for 4 h at 37˚C. Then 100 µl acidic isopropanol (10% SDS, 5% isopropanol and 0.01 mol/l HCl) was added to stop the reaction. The optical density (OD) value was measured at 595 nm using a microplate reader (Epoch; BioTek, Winooski, VT, USA). All experiments were performed in triplicates.
Colony formation assay. Colony formation assay was used to evaluate the colony formation ability of thyroid cancer cells after infected with shTCTN1 or shCon according to previous report (14) . Briefly, cells (600 cells/well) were reseeded on six-well plates and cultured for 12 days to form natural colonies. Then colonies were fixed using 4% paraformaldehyde for 5 min and then stained with 1% crystal violet for 30 sec. The cells were photographed, and the number of colony (more than 50 cells/colony) was counted.
Cell cycle and apoptosis assays. For cell cycle assay, cells were collected, washed with pre-cooling PBS and fixed with cooling 70% ethanol overnight at 4˚C. After washing twice with pre-cooling PBS, the cells were resuspended and incubated in 500 µl PBS containing 50 µg/ml propidium iodide (PI) solution and 100 µg/ml RNase for 30 min at room temperature. For apoptosis assay, cells were assessed with Annexin V-APC/AAD staining (eBioscience Inc., San Diego, CA, USA) on a flow cytometer (BD Biosciences, San Diego, CA, USA) following the manufacturer's instruction. Finally, cells were analyzed on a FACS Calibur cytometer (BD Biosciences). Data were analyzed using CellQuest software.
Statistical analysis. All statistical analyses were performed using SPSS version 13.0 software. The differences between groups were compared using the Student's test, and quantitative data are expressed as the means ± SD of 3 independent experiments. A value of P<0.05 was considered as a statistical significant difference.
Results

Lentivirus-mediated shTCTN1 efficiently knocks down endoge nous expression of TCTN1.
Oncomine database supplied us the TCTN1 expression in thyroid cancer tissues. Hence, TCTN 1 expression levels in thyroid cancer tissues were investigated using publicly available Oncomine database (www.oncomine.org). The results showed that no significant changes of TCTN1 expression were observed in thyroid tumor samples. While considering cancer heterogeneity was a potential challenge of proto-oncogene screening, an outlier analysis was performed in thyroid cancer sample for TCTN1 expression and the outlier was set at 75%. As shown in Fig. 1 , the expression of TCTN 1 showed a significantly increased in 7 databases from different studies. These results demonstrated that TCTN 1 was overexpressed in certain thyroid cancer and may be a proto-oncogene in thyroid cancer.
Now that TCTN1 has been demonstrated overexpressed in thyroid cancer tissue, we deduced that a similar phenomenon may exist in thyroid cancer cell lines. Hence, we determined the expression of TCTN1 in three thyroid cancer cell lines (CAL-62,8305C and TT) and 293T cells. The results were listed in Fig. 1A . It can be seen from the results that TCTN1 expression in thyroid cancer cells was upregulated significant compared with that in 293T cells. In order to explore the biological function of TCTN1 in the thyroid cancer; we used lentivirus-mediated shRNA to knockdown the endogenous TCTN1 gene expression in CAL62 and 8305C cells (undifferentiated carcinoma). After 7 days infection, we observed the GFP fluorescence light under the fluorescence microscope and found higher virus infection rate ( Fig. 2A) . Then we used real-time PCR to check the mRNA expression level of TCTN1, and the results showed that comparing with the control group, the mRNA amount of TCTN1 in the shTCTN1 group was largely decreased (Fig. 2B) . Moreover, western blot analysis also confirmed that TCTN1 protein level in shTCTN1 group was significantly decreased comparing with that in shCon group in CAL62 and 8305C cells (Fig. 2C) . These results showed that, lentivirus-mediated shRNA we designed could efficiently suppress the endogenous TCTN1 in thyroid cancer cells.
However, the current study is affected by several limitations, including the absence of a comparison between TCTN1 expression in tumor tissues and adjacent paired non-cancerous tissues, as well as that in normal thyroid cell lines vs. thyroid cancer cell lines. Thus, further experiments are required to clarify the endogenous expression of TCTN1 in thyroid cancer.
Downregulation of TCTN1 suppressed the cell proliferation in thyroid cancer cells.
Using MTT assay, we went on to check the influence of TCTN1 gene silencing on thyroid cancer cell viability. We observed that after lentivirus infection, the cell proliferation rate of the TCTN1 knockdown group was obviously decreased compared with the control group in both CAL62 and 8305C cells (Fig. 3A) . Furthermore, lots of colonies were observed in cells in the shCon group, but fewer colonies were formed in shTCTN1 group in CAL62 cells (Fig. 3B) . Statistical analysis further demonstrated that the number of colony in shTCTN1 group was decreased by 92.03% (Fig. 3C,  P<0 .001), suggesting that knockdown of TCTN1 significantly impaired the proliferation of thyroid cancer cells.
Downregulation of TCTN1 induced cell cycle arrest.
We used flow cytometer with PI staining to detect the effect of TCTN1 silencing on cell cycle progression in CAL62 and 8305C cells (Fig. 4) . The results ( Fig. 4C and E) revealed that knockdown of TCTN1 induced a decrease in the percentage of cells in G0/G1 phase in CAL62 cells (from 50.86% in shCon to 46.89% in shTCTN1 group, P<0.01) and 8305C cells (from 73.36% in shCon to 61.63% in shTCTN1 group, P<0.01). Notably, we observed a significant increase in percentage of cells in S phase in CAL62 cells and 8305C cells (P<0.001). All these results demonstrated that down regulation of TCTN1 could arrest cell cycle at S phase in CAL62 cells and 8305 cells. Furthermore, more cells were obviously accumulated in the sub-G1 phase representing apoptotic cells in CAL62 and 8305C cells (Fig. 4D and F, P<0 .05).
Downregulation of TCTN1 promoted cell apoptotic in thyroid cancer cells.
To further confirm whether depletion of TCTN1 really promoted cell apoptosis, we used flow cytometer with Annexin V/ADD double staining to determine apoptosis in CAL62 and 8305C cells (Fig. 5A) . After shTCTN1 infection, more cells were presented early (Annexin V+/7-AAD-, P<0.05) and late apoptosis (Annexin V+/7-AAD+, P<0.001) in both CAL62 and 8305C cells (Fig. 5B) .
Downregulation of TCTN1 regulated cell apoptotic and cell cycle markers. Moreover, we detected the expression alterations of apoptotic and cell cycle regulatory molecules. As shown in Fig. 6A and B, the expression levels of cleaved-PARP and cleaved caspase-3 were obviously unregulated in both CAL62 and 8305C cells after TCTN1 knockdown. Additionally, downregulation of TCTN1 slightly suppressed Bcl-2 expression and elevated Bad expression in CAL62 cells, but didn't obviously affect the expression levels of Bcl-2 and Bad in 8305C, which might be ascribed to different cell resource and culture condition. Furthermore, downregulation of TCTN1 decreased Cyclin B1 expression, and increased the expression of CDK2, Cyclin A1 and Cyclin D1 in both CAL62 and 8305C cells (Fig. 6C and D) .
Discussion
The hedgehog pathway, initially discovered by two Nobel laurea tes Dr C. Nusslein-Volhard and Dr E. Wieschaus in Drosophila (15), is a major regulator for cell differentiation, tissue polarity and cell proliferation. Studies from many laboratories reveal activation of this pathway in a variety of human cancer, including basal cell carcinomas (BCCs), medulloblastomas, leukemia, gastrointestinal, lung, ovarian, breast and prostate cancers (16, 17) . TCTN1, as a new discovered Hedgehog pathway bidirectional regulator, could activate/repress the hedgehog signal pathway during mouse embryogenesis (5) . Based on these evidence, we speculated that TCTN1 might play a crucial role in thyroid cancer. Thus, in the present study, we evaluated the functional significance of TCTN1 in thyroid cancer and its potential as a therapeutic target. Lenvitirus-mediated shRNA was firstly designed to specifically targeted TCTN1 gene in thyroid cancer cell lines, CAL62 and 8305C cells. Loss-of-function analysis indicated that knockdown of TCTN1 significantly suppressed cell proliferation and colony formation in thyroid cancer cells. Our data were in accordance with previous report which studied the effects of TCTN1 knockdown in gastric cancer (10) and medulloblastoma (18) . In addition, it should be pointed that the data obtained in the present study should be validated in future Furthermore, we found TCTN1 knockdown could arrest cell cycle at S phase in CAL62 cells and 8305 cells. Consistent with S phase arrest, the expression of cyclin A2 and CDK2, which are known to promote S phase entry in mammals (19, 20) , significantly increased following TCTN1 knockdown. Instead, we observed a dramatic reduction in cyclin B1 levels. Cyclin B1 is a key regulator of cell cycle progression from the S phases to the G2/M phase and its downregulation therefore results in S phase arrest (21) . Similarly, cyclin D1 is involved in normal cell cycle progression. In addition, we observed there was a significant early and late apoptosis in CAL62 and 8305C cells after TCTN1 knockdown, which further demonstrated TCTN1 played a positive role in thyroid cancer cell growth and proliferation. To illuminate the molecular mechanisms by which TCTN1 affected thyroid cancer apoptosis, we detected some molecules associated with cell survival in CAL62 cells after TCTN1 knockdown. The anti-apoptotic protein Bcl-2 plays a pivotal role in regulating cell apoptosis under many adverse conditions, while pro-apoptotic Bad is essential for inducing apoptosis (22) . In our results, reduced Bcl-2 and increased Bad expression suggested silencing TCTN1 might serve as a promoter of cell apoptosis. Notably, a significant proteolytic cleavage of PARP and caspase-3 was detected, also indicating a pro-apoptotic role for TCTN1 knockdown. These results are supported by the previous study that TCTN1 silencing could promote cell apoptosis in pancreatic cancer (12) . Collectively, inhibition of cell proliferation in thyroid cancer induced by TCTN1 knockdown might be closely associated with cell cycle arrest and apoptosis in thyroid cancer cells.
In conclusion, the present study demonstrates that TCTN1 plays a crucial role in promoting thyroid cancer cell growth and proliferation in vitro. The TCTN1-targetd therapy using RNA interference potential application may provide a novel therapy for thyroid cancer. Furthermore, investigations on TCTN1 function in vivo are still necessary for preclinical and clinical studies.
